TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22231734

Group type: EXPERIMENTAL
Intervention: Cevimeline 30 mg orally 3 times daily for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo orally 3 times daily for 6 weeks
Number of subjects: 0
Study: 20236799

Group type: EXPERIMENTAL
Intervention: Addiction Severity Index (ASI) medical composite score (ASImed)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Addiction Severity Index (ASI) psychiatric composite score (ASIpsych)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Maudesley Addiction Profile (MAP) physical health score (MAP-PHS)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Maudesley Addiction Profile (MAP) mental health score (MAP-MHS)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: EuroQol visual analog scale (EQ-VAS)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: EuroQol Group's EQ-5D index score
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Short Form SF-6D index score
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: World Health Organization Disability Assessment Schedule‐II
Number of subjects: 251
Study: 18371101

Group type: EXPERIMENTAL
Intervention: Piezosurgery (test sites)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Conventional rotary diamond burs (control sites)
Number of subjects: 13
Study: 16466011

Group type: COMPARATOR
Intervention: Adiponectin level in type 2 diabetic patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fasting insulin, IL-6, TNFalpha, and HOMA-IR index in type 2 diabetic patients
Number of subjects: 40
Study: 15507957

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 10707793

Group type: EXPERIMENTAL
Intervention: Rituximab 375 mg/m2/week for 4 weeks
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 120
Study: 10170451

Group type: EXPERIMENTAL
Intervention: Dry powder inhaler (Turbuhaler)
Number of subjects: 1004

Group type: COMPARATOR
Intervention: Pressurised metered dose inhaler (pMDI)
Number of subjects: 1004
Study: 8113480

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (B)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Information-based therapy (A1)
Number of subjects: 15
Study: 3533340

Group type: EXPERIMENTAL
Intervention: Pharmacological ionisation with pirprofen (two-dose levels)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Sham ionisation
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo ionisation
Number of subjects: 73
Study: 2972233

Group type: EXPERIMENTAL
Intervention: Doxacurium chloride (10 to 80 micrograms/kg)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Pancuronium (100 micrograms/kg)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Doxacurium (up to 2.7 times the ED95)
Number of subjects: 81
Study: 30956126

Group type: EXPERIMENTAL
Intervention: Screen time ≤2 hours/day, physical activity before and/or during pregnancy, being born outside the United States
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Overall prenatal diet quality
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Dietary components (total vegetables, whole grains, dairy, fatty acids, refined grains, sodium, saturated fats, added sugars)
Number of subjects: 519
Study: 27566696

Group type: EXPERIMENTAL
Intervention: 25 μg vaginal misoprostol
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 26400825

Group type: EXPERIMENTAL
Intervention: Deferral of PCI (Defer group)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Performance of PCI (Perform group)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Reference group (PCI performed as planned)
Number of subjects: 325
Study: 23812762

Group type: EXPERIMENTAL
Intervention: Alcohol (0.6 g/kg for men, 0.55 g/kg for women)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 21893350

Group type: EXPERIMENTAL
Intervention: Preoperative group (patients with recurrent adenotonsillitis)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Post-operative group (patients with recurrent adenotonsillitis)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 47
Study: 20129547

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 1548

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 1548
Study: 16439370

Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg subcutaneously once daily for six to 14 days
Number of subjects: 849

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 849
Study: 14749738

Group type: EXPERIMENTAL
Intervention: beta-Carotene supplementation
Number of subjects: 17767

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17767

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 17767

Group type: COMPARATOR
Intervention: Neither supplement
Number of subjects: 17767
Study: 11346327

Group type: EXPERIMENTAL
Intervention: Experimental written self-disclosure protocol (three 20-minute writing sessions focusing on distressing experiences)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (three 20-minute writing sessions focusing on health behaviors)
Number of subjects: 45
Study: 9403285

Group type: EXPERIMENTAL
Intervention: Mefloquine with food (750 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mefloquine without food (750 mg)
Number of subjects: 20
Study: 7912285

Group type: EXPERIMENTAL
Intervention: Intradermal injections of di‐Lex (III3FucnLc4) for 6 months
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Intradermal injections of tumor associated carbohydrate antigen (TCA) for 6 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Intradermal injections of monomeric Lex
Number of subjects: 70
Study: 3322351

Group type: EXPERIMENTAL
Intervention: Rate responsive pacing (peak rate 125/min)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional fixed rate pacing (VVI, 70/min)
Number of subjects: 10
Study: 31996311

Group type: EXPERIMENTAL
Intervention: Resveratrol (150 mg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 28898473

Group type: EXPERIMENTAL
Intervention: Prucalopride (4 mg oral)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 26990378

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) add-on to liraglutide
Number of subjects: 346

Group type: COMPARATOR
Intervention: Placebo add-on to liraglutide
Number of subjects: 346
Study: 26585622

Group type: EXPERIMENTAL
Intervention: Scaffold oversize group (Dmax smaller than nominal size)
Number of subjects: 1248

Group type: COMPARATOR
Intervention: Scaffold nonoversize group (Dmax larger than nominal size)
Number of subjects: 1248

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1248

Group type: EXPERIMENTAL
Intervention: Scaffold oversize group
Number of subjects: 1248

Group type: EXPERIMENTAL
Intervention: Overlapping scaffolds
Number of subjects: 1248
Study: 23992602

Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 5380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5380
Study: 20877931

Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion program
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Mothers unable to nurse during work shift
Number of subjects: 200
Study: 19093000

Group type: EXPERIMENTAL
Intervention: Acromegaly (AM) group
Number of subjects: 7

Group type: COMPARATOR
Intervention: Healthy control (CON) group
Number of subjects: 7
Study: 16626797

Group type: EXPERIMENTAL
Intervention: Proactive telephone-based peer counseling intervention with up to 6 counseling calls and nicotine replacement therapy (NRT) patches if prepared to quit smoking
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: NRT
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Demographic variables (females, White), higher daily smoking rate, poorer perceived health and moderate perceived risk of smoking
Number of subjects: 398
Study: 12792581

Group type: EXPERIMENTAL
Intervention: Remifentanil (0.1 microg/kg/min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Alfentanil (0.75 microg/kg/min)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remifentanil and alfentanil in association with propofol
Number of subjects: 60
Study: 10367557

Group type: EXPERIMENTAL
Intervention: d-amphetamine (20 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8669996

Group type: EXPERIMENTAL
Intervention: 10 minutes of static stretching exercises interspersed with relaxing (10 subjects)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (6 subjects, untreated)
Number of subjects: 16
Study: 1716810

Group type: EXPERIMENTAL
Intervention: Salmonella typhi Ty21a/V. cholerae Inaba (EX210) vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galactose concentration in media
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S. typhi Ty21a O antigen
Number of subjects: 0
Study: 6412494

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 0
Study: 29898692

Group type: EXPERIMENTAL
Intervention: Twice-weekly sessions of protocolized interpersonal psychotherapy (IPT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Twice-weekly sessions of cognitive behavioral therapy (CBT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Once-weekly sessions of protocolized IPT and CBT
Number of subjects: 15
Study: 26435055

Group type: EXPERIMENTAL
Intervention: Concomitant therapy (10-day regimen)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Sequential therapy (10-day regimen)
Number of subjects: 364
Study: 24845177

Group type: EXPERIMENTAL
Intervention: Lower heart rate variability (HRV)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Heart rate variability (HRV)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Inflammation (IL-6 and CRP)
Number of subjects: 84
Study: 22672993

Group type: EXPERIMENTAL
Intervention: Assisted hatching (AH)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 20536957

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) using premixed insulin lispro mixtures
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG) using basal insulin glargine
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Means of two or more plasma equivalent glucose (PGe) measures
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Receiver-operating characteristic (ROC) curves for PGe to estimate HbA(1c) (< or > 7.0%)
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Overall HbA(1c) measurement
Number of subjects: 623
Study: 18728175

Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OCs)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Lifestyle modification + OCs + Metformin
Number of subjects: 79

Group type: COMPARATOR
Intervention: Combined treatment and placebo
Number of subjects: 79
Study: 15717881

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (L)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention + insulin treatment (L+I)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Insulin treatment alone (I)
Number of subjects: 38
Study: 12187204

Group type: EXPERIMENTAL
Intervention: Transurethral resection plus 100 mg epirubicin
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Transurethral resection plus 50 milliunits interferon-alpha2b
Number of subjects: 200

Group type: COMPARATOR
Intervention: Transurethral resection alone
Number of subjects: 200
Study: 10458419

Group type: EXPERIMENTAL
Intervention: Laparoscopy and open surgery (group 2)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Open surgery only (group 1)
Number of subjects: 61
Study: 7869850

Group type: EXPERIMENTAL
Intervention: New generation combined oral contraceptives (OC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral protein load in OC users
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (comparable controls)
Number of subjects: 0
Study: 2782342

Group type: EXPERIMENTAL
Intervention: Prophylactic transcervical amnioinfusion
Number of subjects: 0
Study: 787014

Group type: EXPERIMENTAL
Intervention: Fenoprofen calcium (200, 400, or 600 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Propoxyphene napsylate (50, 100, or 150 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fenoprofen calcium
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fenoprofen calcium and Propoxyphene napsylate (combined)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 30
Study: 31495887

Group type: EXPERIMENTAL
Intervention: β-blocker use
Number of subjects: 5862

Group type: EXPERIMENTAL
Intervention: β-blocker use (eGFR >60)
Number of subjects: 5862

Group type: EXPERIMENTAL
Intervention: β-blocker use (eGFR 30-60)
Number of subjects: 5862

Group type: EXPERIMENTAL
Intervention: β-blocker use (eGFR <30)
Number of subjects: 5862
Study: 30634618

Group type: EXPERIMENTAL
Intervention: E-cigarette ads with 'brain' warning theme
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: E-cigarette ads with 'chemicals' warning theme
Number of subjects: 876

Group type: EXPERIMENTAL
Intervention: E-cigarette ads with 'relative harm warning' statement
Number of subjects: 876

Group type: COMPARATOR
Intervention: E-cigarette ads with 'standard warning' (absence of RH statement)
Number of subjects: 876
Study: 26609668

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss interventions (PREFER, SELF, SMART)
Number of subjects: 504
Study: 25233649

Group type: EXPERIMENTAL
Intervention: Combined therapy of acupuncture at Xiaojie point and tendon regulation manipulation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acupuncture at Xiaojie point
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tendon-regulation manipulation
Number of subjects: 60
Study: 22004474

Group type: EXPERIMENTAL
Intervention: Nurse specialists as central caregivers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (physicians)
Number of subjects: 0
Study: 20113920

Group type: EXPERIMENTAL
Intervention: HPV vaccine coadministered with dTpa-IPV
Number of subjects: 751

Group type: COMPARATOR
Intervention: dTpa-IPV alone
Number of subjects: 751

Group type: COMPARATOR
Intervention: HPV vaccine alone
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Coadministration of HPV vaccine and dTpa-IPV
Number of subjects: 751
Study: 17544329

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16161914

Group type: EXPERIMENTAL
Intervention: Primary PTCA
Number of subjects: 40

Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 40
Study: 14512127

Group type: EXPERIMENTAL
Intervention: Budesonide 800 pg/d, reduced to 400 pg/d and then 200 pg/d if asthma control maintained
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Fluticasone 800 pg/d, reduced to 400 pg/d and then 200 pg/d if asthma control maintained
Number of subjects: 197
Study: 10944100

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants or aspirin after infrainguinal bypass surgery
Number of subjects: 2650

Group type: EXPERIMENTAL
Intervention: Femoropopliteal bypasses
Number of subjects: 2650

Group type: EXPERIMENTAL
Intervention: Femorocrural bypass grafts
Number of subjects: 2650

Group type: COMPARATOR
Intervention: First model (history and clinical examination)
Number of subjects: 2650

Group type: EXPERIMENTAL
Intervention: Second model (including radiological and surgical data)
Number of subjects: 2650
Study: 2070391

Group type: EXPERIMENTAL
Intervention: Buffered lidocaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard lidocaine
Number of subjects: 20
Study: 6342398

Group type: EXPERIMENTAL
Intervention: Pressure patching
Number of subjects: 41

Group type: COMPARATOR
Intervention: Unpatched group (control)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Patients with bullous keratopathy
Number of subjects: 41
Study: 30639342

Group type: EXPERIMENTAL
Intervention: Testosterone gel
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 93
Study: 29937195

Group type: EXPERIMENTAL
Intervention: Personalised e‐health‐care programme
Number of subjects: 344

Group type: COMPARATOR
Intervention: Usual care and access to a placebo website
Number of subjects: 344
Study: 26636426

Group type: EXPERIMENTAL
Intervention: Group Cognitive Processing Therapy - Cognitive only version (CPT-C)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Group Present-Centered Therapy (PCT)
Number of subjects: 108
Study: 24998546

Group type: COMPARATOR
Intervention: Comprehensive-SFL state
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: SHS exposure in public transport
Number of subjects: 898
Study: 22970177

Group type: EXPERIMENTAL
Intervention: Fully integrated services (ANC, PMTCT, and HIV treatment services all delivered in the ANC clinic)
Number of subjects: 1172

Group type: COMPARATOR
Intervention: Non-integrated services (ANC clinics provided ANC and basic PMTCT services and referred clients to a separate HIV clinic for HIV treatment)
Number of subjects: 1172
Study: 20233625

Group type: EXPERIMENTAL
Intervention: High immunohistochemical (IHC) expression of cyclin E
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-detectable immunoblot expression of maspin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High CD105-microvessel density (MVD) in tumor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low IHC expression of BRCA1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CA/AA versus CC genotypes in C8092A in ERCC1
Number of subjects: 0
Study: 17341568

Group type: EXPERIMENTAL
Intervention: 200 microg PYY(3‐36) t.i.d.
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: 600 microg PYY(3‐36) t.i.d.
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 15531753

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP200), 200 microg daily for 3 months
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP200)
Number of subjects: 65
Study: 11985942

Group type: EXPERIMENTAL
Intervention: Micronutrient-containing beverage (12 oz daily for 6 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (12 oz daily for 6 weeks)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Micronutrient-containing beverage
Number of subjects: 31
Study: 9805319

Group type: EXPERIMENTAL
Intervention: Rehearsal
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reading control task
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rehearsal and reading rates
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Rehearsal list length
Number of subjects: 12
Study: 7720911

Group type: EXPERIMENTAL
Intervention: Expanded polytetrafluoroethylene (PTFE; Gore‐Tex Surgical Membrane)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oxidized regenerated cellulose (Interceed TC7)
Number of subjects: 32
Study: 1962277

Group type: EXPERIMENTAL
Intervention: 2 Gy per fraction
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: 5.4 Gy per fraction
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Various fractionation regimens (2 Gy, 3 Gy, 4 Gy, 5.4 Gy)
Number of subjects: 203
Study: 6786796

Group type: EXPERIMENTAL
Intervention: Flunisolide nasal spray
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sodium cromoglycate nasal spray
Number of subjects: 67
Study: 30978438

Group type: EXPERIMENTAL
Intervention: Immediate Dentin Sealing (IDS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Delayed Dentin Sealing (DDS)
Number of subjects: 60
Study: 28665038

Group type: EXPERIMENTAL
Intervention: M. chamomilla L., M. officinalis L. and tyndallized L. acidophilus (HA122) (Colimil® Plus®)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: L. reuteri DSM 17938
Number of subjects: 176

Group type: COMPARATOR
Intervention: Simethicone
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: M. chamomilla L., M. officinalis L. and tyndallized L. acidophilus (HA122)
Number of subjects: 176
Study: 27686173

Group type: EXPERIMENTAL
Intervention: On-site support for laboratory staff
Number of subjects: 128
Study: 24812193

Group type: EXPERIMENTAL
Intervention: Mii‐vitaliSe intervention (Nintendo Wii)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (delayed intervention after 6 months)
Number of subjects: 30
Study: 21412266

Group type: EXPERIMENTAL
Intervention: Candesartan (12 mg per day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Candesartan (8 mg per day) plus amlodipine (2.5 mg per day)
Number of subjects: 0
Study: 19347682

Group type: EXPERIMENTAL
Intervention: General practitioners' adherence to clinical guidelines for dementia diagnosis and management
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Documentation of the diagnostic process in dementia syndromes
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Management processes for dementia in primary care
Number of subjects: 450
Study: 17634896

Group type: EXPERIMENTAL
Intervention: MML group (moxifloxacin 400 mg/d, metronidazole 400 mg twice daily, lansoprazole 30 mg twice daily)
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: MAL group (moxifloxacin 400 mg/d, amoxicillin 1 g twice daily, lansoprazole 30 mg twice daily)
Number of subjects: 277

Group type: COMPARATOR
Intervention: CML group (clarithromycin 500 mg twice daily, metronidazole 400 mg twice daily, lansoprazole 30 mg twice daily)
Number of subjects: 277

Group type: COMPARATOR
Intervention: CAL group (clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily, lansoprazole 30 mg twice daily)
Number of subjects: 277
Study: 15163941

Group type: EXPERIMENTAL
Intervention: Remote echocardiography using a handheld echocardiographic device with satellite transmission
Number of subjects: 12
Study: 11722487

Group type: EXPERIMENTAL
Intervention: Topical skin lipid mixture containing ceramide‐3 and patented nanoparticles
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Topical skin lipid mixture in combination with topical corticosteroids
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Skin lipid mixture
Number of subjects: 580

Group type: COMPARATOR
Intervention: Control (Topical corticosteroids alone)
Number of subjects: 580
Study: 9826042

Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 42

Group type: COMPARATOR
Intervention: ECCE
Number of subjects: 42